ClearRock

ClearRock Biologics is a Boston-based biotechnology company specializing in the development of next-generation multi-specific antibody therapeutics. The company utilizes a proprietary engineering platform to design biologics capable of simultaneously binding to multiple disease-relevant targets, with a primary focus on oncology and immunology. Founded by a team of experienced industry leaders, ClearRock aims to address complex disease biology and overcome limitations of current monoclonal antibody therapies. The company's approach emphasizes the creation of highly potent and selective molecules to improve patient outcomes in areas of significant unmet medical need. Its leadership team brings deep expertise from major pharmaceutical organizations, positioning the company to advance a pipeline of differentiated antibody candidates.